Volume : 09, Issue : 03, March – 2022
Title:
31.FORMULATION OF DEXTROMETHORPHAN HYDROBROMIDE EXTENDED-RELEASE SUSPENSION AND EVALUATION
Authors :
Pavani Sure*, Dr.N. Sandeepthi
Abstract :
Dextromethorphan hydrobromide is a synthetic anti tussive agents. Biological half-life of this drug is 2-4hrs. Due to its half-life, the dose is employed 4times a day. To reduce the dose frequency and to improve the patient compliance, the extended-release suspension of dextromethorphan polistirex was formulated with PEG coating and Enteric coating. In the present study the extended-release suspension of dextromethorphan polistirex was prepared and physical mixture of the drug and polymer was found to be compatible after the comparative study of three months. The extended-release suspension of dextromethorphan polistirex was evaluated by FTIR, DSC and other parameters. Difference factor (f2) was used as a statistical method in this work.The formulation showed advantages in the terms of patient compliance, safety, and better transportation over existing suspension formulation.
Key words: Dextromethorphan polistirex, Surelease Dispersion, Delsym.
Cite This Article:
Please cite this article in press Pavani Sure et al, Formulation Of Dextromethorphan Hydrobromide Extended Release Suspension And Evaluation., Indo Am. J. P. Sci, 2022; 09(3),.
Number of Downloads : 10
References:
1. Cooper & Gun, Sixth edition, “Dispersed system” Tutorial Pharmacy, Page No. 75-78.
2. Aulton M.E. Second edition, “Suspension” Pharmaceutics-The Science of Dosage Form Design, Churchill Livingstone, Edinburgh 2002, Page
No. 84-86, 273.
3. Banker G.S.. Rhodes C.T. “Dispersed systems” Modern Pharmaceutics, Marcel Dekker, INC. New York 1979. Vol-72, Page No. 345-346.
4. Subramanyam C.V.S., Second edition, “Suspensions” Text Book of Physical Pharamaceutics, Page
No. 374-387.
5. Ansel C., Allen L.V., Popovich N.G. Eighth edition “Disperse systems” Pharmaceutical Dosage Forms & Drug Delivery Systems, Lippincott Williams and Wilkins, Philadelphia 2005, Page No. Page No. 387-389, 398.
6. A. Martin and J. Swarbrick, Sixth edition, in sprowls, American Pharmacy, Lippincott, Philadelphia 1966, Page No. 205.
7. Soci M.M. and Parrot E.L., J. Pharm Sci., 1980:69:403.
8. Ludwing A. and Ooteghen, M. Van, Drug Dev. Ind. Pharm. 1988:14:2267.
9. Pennington A.K., Ractlife J.H., Wilson C.G. and Hardy J.G., Int. J. Pharm., 1988:43:221
10. Dicolo G., Carelli V., Giannacciini B., Serafini M.F., and Bottari F., J. Pharm.
Sci.,1980:69:387.
11. Lachman L, Third edition, “Pharmaceutical Suspension” The Theory and Practice of Industrial Pharmacy, Verghese Publishing House, Bombay 1996, Page No:488-489.
12. Jani G.K. Fourth edition, “Liquid Dosage Forms” Pharmacutics-II (Dispensing Pharmacy), B.S. Shah Prakashan, Ahmedabad 2004, Page No. 202.
13. “Pharmaceutical Formulations” U.S. Patent No. 4,996,222.
14. www.gmpua.com/RD/RD/HandbookPharmaceutical%20Excipients.pdf
15. https://www.researchgate.net/…/Handbook-of-pharmaceutical-excipients-6th-edition.pdf